Cleerly vs Nanox.AI (2026)
Two ways to find coronary disease on a computed tomography scan. Cleerly analyses the coronary study a cardiologist ordered, quantifying plaque and stenosis to answer a contested question about who needs invasive testing. Nanox mines scans taken for entirely different reasons, surfacing coronary calcium and vertebral fractures nobody was looking for, with a clearance portfolio built over years and a listed parent whose filings describe the business. The difference is who asked the question. Cleerly answers one a clinician already posed; Nanox raises one nobody did, which is genuine population health and also generates follow up obligations the health system pays for. Price the incidental finding pathway alongside the license, because the vendor does not carry it.
- Coronary plaque quantification from computed tomography is the product, aimed at a specific and contested clinical decision about who needs invasive testing.
- Depth in one disease with a real evidence base is a different proposition from opportunistic breadth across findings.
- For a cardiology service the analysis answers the question the service already asks every day.
- Its strategy is opportunistic population health, mining scans taken for another reason to find findings nobody was looking for, including vertebral fractures and coronary calcium.
- A deep clearance portfolio built over years across several anatomical findings, which is a harder path than a single authorization.
- As a subsidiary of a listed parent, its business is described in filed disclosures that private competitors do not produce.
This comparison is published by AI Health Index, an independent research platform that compares healthcare AI vendors objectively. Cleerly and Nanox.AI are each graded against the same capability taxonomy, from each vendor's own public materials and the regulatory record, under the AI Health Index verification standard. No vendor pays for placement, and no vendor has reviewed this page. How this evidence is graded
Plain facts
| Fact | Cleerly | Nanox.AI |
|---|---|---|
| Primary category | Radiology & Imaging AI | Radiology & Imaging AI |
| Founded | 2017 | 2014 |
| Headquarters | Denver, Colorado, United States | Neve Ilan, Israel |
| Website | cleerlyhealth.com | nanox.vision |
Side by Side
Select any grade to read the note behind it.
Each vendor in one paragraph
Written to be quoted whole. Each paragraph opens the AI Health Index profile of the vendor: what the product is, who buys it and what it does.
Cleerly applies AI to coronary CT angiography to quantify and characterize atherosclerotic plaque and estimate ischemia without an invasive test. Cleerly Labs, web based analysis cleared in 2020, measures plaque volume, composition, length and location and stenosis on CCTA from any scanner; Cleerly ISCHEMIA, cleared in 2023 (K231335), estimates vessel level ischemia as a diagnostic aid; Cleerly COMPARE tracks change between scans.
Source: AI Health Index, August 2026
Imaging AI business of Nasdaq listed Nano-X Imaging, formerly Zebra Medical Vision, acquired in November 2021. Its solutions analyze CT scans already acquired for other reasons to surface undiagnosed chronic disease: HealthOST for vertebral height loss and bone mineral density, HealthCCSng for coronary artery calcium on non gated chest CT, and HealthFLD for liver density in fatty liver disease.
Source: AI Health Index, August 2026
Questions buyers ask
How do Cleerly and Nanox.AI work with the EHR?
Cleerly operates as a CCTA analysis service that returns a physician report, sitting in the cardiac imaging and reporting pathway rather than integrating deeply with the EHR.
With Nanox.AI, the AI page describes integration with PACS, record and reporting systems, and record integration to streamline patient care, and names Corewell Health, Atlantic Health System, Jefferson Einstein Hospital, Rabin Medical Center and NHS hospitals as users. The HealthVCF summary describes findings shown in a standalone worklist application. From the AI Health Index, drawn from each vendor's own published materials and the regulatory record, verified August 4, 2026. No vendor pays for placement.
How are Cleerly and Nanox.AI priced and sold?
Cleerly publishes billing guidelines, coverage pages and a payer policy lookup tool: AI plaque analysis of coronary CT carries Category I CPT code 75577 from January 2026, ISCHEMIA is billable under Category I code 75580, and Medicare contractor and commercial payer policies are reported to cover more than 86 million lives.
For Nanox.AI, the parent, a Nasdaq listed company, describes its business model in securities filings, including software as a service billing and a pay per scan model for its imaging hardware. Whether the AI solutions are licensed per scan, per site or per population is not stated, and the answer changes the cost of running a screening program across a whole archive. From the AI Health Index, drawn from each vendor's own published materials and the regulatory record, verified August 4, 2026. No vendor pays for placement.
Which settings and specialties do Cleerly and Nanox.AI cover?
Cleerly Labs analyzes CCTA from any CT scanner for patients with known or suspected coronary artery disease, and ISCHEMIA estimates vessel level ischemia as a diagnostic aid; COMPARE tracks change between scans. ISCHEMIA was validated in stable patients referred for non-emergent invasive angiography at 23 centers in and outside the US, with results reported for both.
In Nanox.AI's case, the liver solution's validation is not described on the AI page. From the AI Health Index, drawn from each vendor's own published materials and the regulatory record, verified August 4, 2026. No vendor pays for placement.
What evidence is published for Cleerly and Nanox.AI?
For Cleerly, a post-hoc analysis of the PACIFIC trial compared it with FFRCT, PET and SPECT against invasive FFR, and the international CONFIRM2 registry links quantified plaque burden to risk. The company's claims that ISCHEMIA was more accurate than FFRCT and stress testing and was the only non-invasive ischemia test prognostic of later events come from its own analyses of CREDENCE and PACIFIC.
With Nanox.AI, the HealthVCF 510(k) summary (K192901, 2020) reports a standalone test on 611 cases against three US board certified radiologists. From the AI Health Index, drawn from each vendor's own published materials and the regulatory record, verified August 4, 2026. No vendor pays for placement.
Related comparisons
Other published head to head assessments involving these vendors or their closest peers. The full set for this category is on the Clinical Decision Support page.
Opportunistic detection creates a duty to act whose cost falls on the health system rather than the vendor, since a surfaced finding generates follow up imaging, patient notification and an incidental finding pathway, and that should be priced alongside the license. Nanox publishes no health privacy commitment, no data governance framework and no subgroup analysis, which is a notable gap for a product designed to run across whole populations. Neither vendor publishes performance stratified by sex, which matters because coronary disease presentation and calcium scoring both differ.